093 - Ophthalmology Gene Therapies STUMBLE but REGENXBIO and FDMT Could Turn it Around in H2-2021

Various companies in the Ophthalmology gene therapy space saw upsets from either an efficacy, safety or collaboration standpoint. However, three related companies have upcoming catalysts in the second half of 2021 that could turn sentiment around. They are: 4D Molecular Therapeutics, REGENXBIO and Clearside Biomedical. In this episode, I talk about eye diseases caused by neovascularization, discuss the sector as it stands today and explain my investment theses for each of those 3 companies.
I also talk about the troublesome position Biogen has found themselves in and what my plan is for the position I have in the company.
Check out our NEW sponsor: BiopharmIQ, which is the best place to get consolidated information about small-mid cap biotechs. Use my link here to let them know that I sent you: bit.ly/3iwVGbu
Presentation slides: drive.google.c...
Help out the show (or join the discord) by becoming a patron at: / breakingbiotech
Follow me on twitter @matthewlepoire
Send me an email [e-mail]
www.breakingbiotech.com #breakingbiotech
Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

[@biobagholder8081]

Video has me interested in Clearside for sure. Thanks for the coverage as always, Matt!

[@breakingbiotech]

Thank you!

[@biobagholder8081]

The Yumanity delay was so ridiculous and last second that it has me largely expecting negative data. I wish longs (and Parkinsons patients) luck though!

[@breakingbiotech]

Ya, it hurt me. Very disappointing.